Sale by Michael Wortley of 414 shares of Reata Pharmaceuticals
RETADelisted Stock | USD 172.36 0.02 0.01% |
About 56% of Reata Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Reata Pharmaceuticals suggests that many traders are alarmed regarding Reata Pharmaceuticals' prospects. Reata Pharmaceuticals' investor sentiment overview provides quick insight into current market opportunities from investing in Reata Pharmaceuticals. The current market sentiment, together with Reata Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Reata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Reata Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Reata daily returns and investor perception about the current price of Reata Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Reata |
Filed transaction by Reata Pharmaceuticals Inc officer. General open market or private sale of non-derivative or derivative security
Read at macroaxis.com
Reata Pharmaceuticals Fundamental Analysis
We analyze Reata Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Reata Pharmaceuticals is currently under evaluation in shares owned by institutions category among related companies. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Reata Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reata Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Reata Pharmaceuticals Related Equities
SRPT | Sarepta Therapeutics | 6.09 | ||||
TERN | Terns Pharmaceuticals | 1.28 | ||||
VKTX | Viking Therapeutics | 0.22 | ||||
MDGL | Madrigal Pharmaceuticals | 0.00 | ||||
PTCT | PTC Therapeutics | 0.79 | ||||
VIR | Vir Biotechnology | 1.11 | ||||
KRYS | Krystal Biotech | 1.85 | ||||
CVAC | CureVac NV | 3.46 | ||||
AKRO | Akero Therapeutics | 3.52 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |